(GLUE) Monte Rosa Therapeutics - Overview
Stock: MGD Pipeline, MRT-2359, MRT-6160, MRT-8102
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 107% |
| Relative Tail Risk | -12.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.47 |
| Alpha | 171.02 |
| Character TTM | |
|---|---|
| Beta | 0.927 |
| Beta Downside | 0.422 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.24% |
| CAGR/Max DD | 0.60 |
Description: GLUE Monte Rosa Therapeutics December 31, 2025
Monte Rosa Therapeutics (NASDAQ: GLUE) is a clinical-stage biotech that builds orally bioavailable “molecular glue degraders” (MGDs) to flag disease-relevant proteins for destruction, targeting MYC-driven cancers (MRT-2359), autoimmune/inflammatory disorders (MRT-6160), and IL-1β/NLRP3-mediated inflammation (MRT-8102). The firm also pursues CDK2-directed oncology programs and leverages its QuEEN discovery engine to accelerate target-centric MGD design.
As of the latest 10-Q (Q2 2024), Monte Rosa reported $115 million of cash and marketable securities, enough runway to fund R&D through late 2025; its R&D spend rose 38 % YoY to $28 million, reflecting accelerated preclinical and early-phase trials. The strategic partnership with F. Hoffmann-La Roche includes a $30 million upfront payment and tiered milestones that could exceed $300 million if multiple MGD candidates advance.
The precision-medicine segment of biotech is expanding at a CAGR of roughly 12 % (2022-2027), driven by demand for targeted therapies and the growing acceptance of protein-degradation modalities, positioning Monte Rosa’s MGD platform to capture a share of an estimated $8 billion market for next-generation degraders.
For a deeper, data-rich view of GLUE’s valuation and risk profile, you might find ValueRay’s analyst notes worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 20.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.32 > 0.02 and ΔFCF/TA 51.46 > 1.0 |
| NWC/Revenue: 187.5% < 20% (prev 883.2%; Δ -695.7% < -1%) |
| CFO/TA 0.32 > 3% & CFO 149.1m > Net Income 20.9m |
| Net Debt (-168.2m) to EBITDA (19.6m): -8.60 < 3 |
| Current Ratio: 6.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.4m) vs 12m ago 0.47% < -2% |
| Gross Margin: 96.54% > 18% (prev 0.67%; Δ 9587 % > 0.5%) |
| Asset Turnover: 46.85% > 50% (prev 7.53%; Δ 39.32% > 0%) |
| Interest Coverage Ratio: -1.05 > 6 (EBITDA TTM 19.6m / Interest Expense TTM -10.7m) |
Altman Z'' -0.14
| A: 0.74 (Total Current Assets 401.8m - Total Current Liabilities 61.4m) / Total Assets 459.8m |
| B: -0.94 (Retained Earnings -431.1m / Total Assets 459.8m) |
| C: 0.03 (EBIT TTM 11.2m / Avg Total Assets 387.5m) |
| D: -2.03 (Book Value of Equity -434.3m / Total Liabilities 214.0m) |
| Altman-Z'' Score: -0.14 = B |
Beneish M 1.00
| DSRI: 1.09 (Receivables 4.96m/595.0k, Revenue 181.5m/23.7m) |
| GMI: 0.69 (GM 96.54% / 66.68%) |
| AQI: 0.72 (AQ_t 0.01 / AQ_t-1 0.02) |
| SGI: 7.65 (Revenue 181.5m / 23.7m) |
| TATA: -0.28 (NI 20.9m - CFO 149.1m) / TA 459.8m) |
| Beneish M-Score: 1.09 (Cap -4..+1) = D |
What is the price of GLUE shares?
Over the past week, the price has changed by -4.73%, over one month by +22.11%, over three months by +50.27% and over the past year by +184.16%.
Is GLUE a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GLUE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.8 | 72.9% |
| Analysts Target Price | 33.8 | 72.9% |
| ValueRay Target Price | 20 | 2.4% |
GLUE Fundamental Data Overview February 01, 2026
P/E Forward = 10.02
P/S = 8.9708
P/B = 6.5532
Revenue TTM = 181.5m USD
EBIT TTM = 11.2m USD
EBITDA TTM = 19.6m USD
Long Term Debt = 40.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.24m USD (from shortTermDebt, last quarter)
Debt = 40.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -168.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.28b USD (1.63b + Debt 40.2m - CCE 391.3m)
Interest Coverage Ratio = -1.05 (Ebit TTM 11.2m / Interest Expense TTM -10.7m)
EV/FCF = 8.81x (Enterprise Value 1.28b / FCF TTM 145.0m)
FCF Yield = 11.35% (FCF TTM 145.0m / Enterprise Value 1.28b)
FCF Margin = 79.89% (FCF TTM 145.0m / Revenue TTM 181.5m)
Net Margin = 11.54% (Net Income TTM 20.9m / Revenue TTM 181.5m)
Gross Margin = 96.54% ((Revenue TTM 181.5m - Cost of Revenue TTM 6.28m) / Revenue TTM)
Gross Margin QoQ = 83.59% (prev 90.84%)
Tobins Q-Ratio = 2.78 (Enterprise Value 1.28b / Total Assets 459.8m)
Interest Expense / Debt = 2.33% (Interest Expense 935.0k / Debt 40.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 8.87m (EBIT 11.2m * (1 - 21.00%))
Current Ratio = 6.54 (Total Current Assets 401.8m / Total Current Liabilities 61.4m)
Debt / Equity = 0.16 (Debt 40.2m / totalStockholderEquity, last quarter 245.8m)
Debt / EBITDA = -8.60 (Net Debt -168.2m / EBITDA 19.6m)
Debt / FCF = -1.16 (Net Debt -168.2m / FCF TTM 145.0m)
Total Stockholder Equity = 253.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.41% (Net Income 20.9m / Total Assets 459.8m)
RoE = 8.28% (Net Income TTM 20.9m / Total Stockholder Equity 253.0m)
RoCE = 3.83% (EBIT 11.2m / Capital Employed (Equity 253.0m + L.T.Debt 40.2m))
RoIC = 3.51% (NOPAT 8.87m / Invested Capital 253.0m)
WACC = 9.15% (E(1.63b)/V(1.67b) * Re(9.33%) + D(40.2m)/V(1.67b) * Rd(2.33%) * (1-Tc(0.21)))
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 25.48%
[DCF Debug] Terminal Value 65.19% ; FCFF base≈145.0m ; Y1≈95.2m ; Y5≈43.4m
Fair Price DCF = 11.49 (EV 708.1m - Net Debt -168.2m = Equity 876.3m / Shares 76.2m; r=9.15% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 66.44 | EPS CAGR: 34.04% | SUE: 0.74 | # QB: 0
Revenue Correlation: 86.02 | Revenue CAGR: 331.7% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.48 | Chg30d=-0.017 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.38 | Chg30d=-0.011 | Revisions Net=+0 | Growth EPS=-555.0% | Growth Revenue=-59.2%